Analyst Reco. Cellectis S.A.

Equities

ALCLS

FR0010425595

Real-time Euronext Paris Other stock markets 05:20:13 2024-05-06 am EDT			5-day change	1st Jan Change
2.86 ^EUR	+3.62%		+16.73%	+3.47%

10:23am	Cellectis Secures $140 Million Additional Equity Investment From AstraZeneca	MT
09:59am	AstraZeneca: equity investment in Cellectis	CF

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

European Earnings, Rate-hike Predictions Push French Stocks to Red	23-04-25	MT
Citigroup Adjusts Cellectis Price Target to $16 From $24, Maintains Buy Rating	23-04-05	MT
Oppenheimer Adjusts Cellectis Price Target to $13 From $16, Maintains Outperform Rating	23-03-13	MT
Goldman Sachs Adjusts Cellectis' Price Target to $2 from $3, Keeps Sell Rating	22-05-24	MT
Baird Upgrades Cellectis to Outperform From Neutral	22-05-18	MT
Barclays Lowers Cellectis S.A's Price Target to $7 From $9, Overweight Rating Maintained	22-05-13	MT
Wells Fargo Downgrades Cellectis to Equalweight From Overweight; Price Target is $16	22-01-06	MT
JMP Securities Starts Cellectis at Market Outperform With $20 Price Target	21-11-30	MT
CELLECTIS S A : Baird Downgrades Cellectis to Neutral from Outperform, Adjusts Price Target to $10 from $39	21-10-08	MT
CELLECTIS S A : Guggenheim Downgrades Cellectis to Neutral from Buy	21-04-28	MT
CELLECTIS S A : Baird Upgrades Cellectis to Outperform From Neutral, Adjusts Price Target to $39 From $23	21-03-16	MT
Cellectis S.A. and Pfizer Inc. Completes Remission Rate Across Two Phase I Adult and Pediatric Acute Lymphoblastic Leukemia Trials	17-12-12	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.

SIGN UP NOW